Skip to main content

Table 4 Correlation between PIK3CA mutation and clinical variables in estrogen receptor (ER)-positive and ER-negative tumors

From: PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer

   Patients with ER-negative breast cancer Patients with ER-positive breast cancer
   PIK3CA wild-type (n = 54) PIK3CA mutation (n = 8) P valuea PIK3CA wild-type (n = 63) PIK3CA mutation (n = 15) P valuea
Pathological complete response (pCR) versus residual disease (RD) RD 38 (72%) 5 (71%) 1.000 57 (92%) 13 (87%) 0.617
  pCR 15 (28%) 2 (29%)   5 (8%) 2 (13%)  
  Unknown 1 1 - 1 - -
Residual cancer burden 0 15 (34.1%) 2 (50.0%) 0.616 (0.527b) 5 (10.6%) 2 (18.2%) 0.221 (0.543b)
  I 3 (6.8%) 0 (0%)   4 (8.5%) 0 (0%)  
  II 15 (34.1%) 2 (50.0%)   22 (46.8%) 8 (72.7%)  
  III 11 (25.0%) 0 (0%)   16 (34.0%) 1 (9.1%)  
  Unknown 10 4 - 16 4 -
HER2 status HER2- 47 (87%) 7 (88%) 1.000 57 (90%) 14 (93%) 0.617
  HER2+ 7 (13%) 1 (12%)   6 (10%) 1 (7%)  
Grade Grade 1–2 9 (20%) 2 (33%) 0.598 37 (71%) 8 (67%) 0.739
  Grade 3 36 (80%) 4 (67%)   15 (29%) 4 (33%)  
  Unknown 9 2 - 11 3 -
Nodal status Negative 15 (28%) 4 (50%) 0.235 14 (22%) 8 (53%) 0.025
  Positive 39 (72%) 4 (50%)   49 (78%) 7 (47%)  
Tumor size T0 0 (0%) 0 (0%) 0.937 1 (2%) 1 (7%) 0.715
  T1 4 (7%) 0 (0%)   3 (5%) 0 (0%)  
  T2 26 (48%) 4 (50%)   33 (52%) 8 (53%)  
  T3 10 (18%) 1 (12%)   8 (13%) 2 (13%)  
  T4 14 (26%) 3 (38%)   18 (28%) 4 (27%)  
Ethnicity Asian 1 (2%) 0 (0%) 0.326 1 (2%) 1 (7%) 0.478
  Black 6 (11%) 2 (25%)   5 (8%) 0 (0%)  
  Hispanic 16 (30%) 4 (50%)   24 (38%) 6 (40%)  
  Caucasian 31 (57%) 2 (25%)   33 (52%) 8 (53%)  
Median age (minimum-maximum), years   51 (28–73) 56.5 (42–73) - 50 (28–73) 52 (43–73)  
  1. aChi-square test. b P value for comparison of residual cancer burden (RCB)-0 and RCB-I versus RCB-III. PIK3CA, phosphatidylinositol 3-kinase, catalytic, alpha polypeptide.